Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
2.480
+0.110 (4.64%)
At close: Oct 9, 2026, 4:00 PM EDT
2.350
-0.130 (-5.24%)
After-hours: Oct 9, 2026, 7:04 PM EDT
Longeveron Revenue
Longeveron had revenue of $287.00K in the quarter ending June 30, 2026, a decrease of -9.18%. This brings the company's revenue in the last twelve months to $1.19M, down -42.74% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%. That makes Longeveron the 43,297th largest company in the world by revenue and 6,009th in the United States.
Revenue (ttm)
$1.19M
Revenue Growth
-42.74%
P/S Ratio
6.66
Revenue / Employee
$31,237
Employees
38
Market Cap
7.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.50M |
| Traws Pharma | 2.73M |
| Azitra | 7.50K |
| Aprea Therapeutics | 5.19K |
| Soligenix | 2.34K |
LGVN News
- 9 days ago - Longeveron to Participate in Three Longevity/Aging Investment Conferences - GlobeNewsWire
- 22 days ago - Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial - TipRanks
- 23 days ago - Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition - Reuters
- 23 days ago - Longeveron down 55% at $2.98 after resumption of trade - TheFly
- 23 days ago - Longeveron Inc trading resumes - TheFly
- 23 days ago - Longeveron to resume trading at 5:55 pm ET - TheFly
- 23 days ago - Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial - TheFly
- 23 days ago - Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) - GlobeNewsWire